Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

C0690500

Ceftazidime

European Pharmacopoeia (EP) Reference Standard

Synonyma:

Ceftazidime pentahydrate

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C22H22N6O7S2 · 5H2O
Číslo CAS:
78439-06-2
Molekulová hmotnost:
636.65
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ceftazidime

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1

InChI key

NMVPEQXCMGEDNH-TZVUEUGBSA-N

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ceftazidime EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Č. produktu
Popis
Stanovení ceny

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H317,H334

Hazard Classifications

Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 9

1 of 9

vibrant-m

Y0000420

Cefotaxime acid

vibrant-m

P1890000

Piperacillin

Tobramycin Aminoglycoside antibiotic

Sigma-Aldrich

T4014

Tobramycin

Imipenem monohydrate ≥98% (HPLC)

Sigma-Aldrich

I0160

Imipenem monohydrate

Sulfamethoxazole European Pharmacopoeia (EP) Reference Standard

S2100000

Sulfamethoxazole

vibrant-m

A0368000

Amikacin

Meropenem United States Pharmacopeia (USP) Reference Standard

USP

1392454

Meropenem

Ceftriaxone sodium British Pharmacopoeia (BP) Reference Standard

BP976

Ceftriaxone sodium

Supelco

Supelco

PHR1763

Cefepime hydrochloride

Anu Kantele et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(6), 837-846 (2015-01-24)
More than 300 million travelers visit regions with poor hygiene annually. A significant percentage of them become colonized by resistant intestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) and may transmit the strains to others and to medical care settings
Johanna Berkhout et al.
Antimicrobial agents and chemotherapy, 59(2), 1138-1144 (2014-12-10)
To evaluate the in vitro effects of the combination of ceftazidime and avibactam on the MICs of both compounds, checkerboard assays were performed for 81 clinical strains, including 55 Enterobacteriaceae strains (32 Klebsiella pneumoniae, 19 Escherichia coli, 1 Citrobacter freundii
S Segal-Maurer et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 28(5), 1134-1138 (1999-08-19)
Increasing prevalence of multidrug-resistant gram-negative organisms has led to a rise in clinically significant infections with these organisms and an increasing therapeutic dilemma. We present a case of a neurosurgical patient who developed ventriculoperitoneal shunt-associated ventriculitis due to ceftazidime-resistant Klebsiella
Jason A Roberts et al.
International journal of antimicrobial agents, 29(2), 117-128 (2006-12-13)
Sepsis and nosocomial infections continue to be a significant problem in intensive care, contributing heavily to mortality and prolonged hospital stay. Early and appropriate antibiotic therapy is critical for optimising outcomes. However, the emergence of highly resistant bacteria, coupled with
Sofiya N Micheva-Viteva et al.
mSystems, 5(1) (2020-02-13)
Persister cells are genetically identical variants in a bacterial population that have phenotypically modified their physiology to survive environmental stress. In bacterial pathogens, persisters are able to survive antibiotic treatment and reinfect patients in a frustrating cycle of chronic infection.
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.